(Reuters) -Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda, ...

Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as upfront and milestone payments from vaccine supply and licensing deals helped offset pressure ​from sagging demand, ...

Why Novavax Stock Is Back on Investor Radars Novavax (NVAX) has been catching investor attention again after recent trading swings, with the stock closing at US$9.06 and showing mixed short term ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Add Yahoo as a preferred source to see more of our stories on Google. Food and Drug Administration commissioner Martin Markary speaks during an event in the Roosevelt Room at the White House, Monday, ...

Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the Gaithersburg-based company said Wednesday. The news ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...